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Cardiovascular complications are a major problem in chronic
renal failure. We examined the effects of plasma calcium,
phosphate, parathyroid hormone (PTH), and calcitriol on
cardiac morphology in 5/6 nephrectomized rats. Fifteen
weeks after nephrectomy rats were given a control diet,
high-calcium or -phosphorus diet, or given paricalcitol
treatment for 12 weeks. Sham-operated rats were on a
control diet. Blood pressure, plasma phosphate, and PTH
were increased, while the creatinine clearance was reduced
in remnant kidney rats. Phosphate and PTH were further
elevated by the high-phosphate diet but suppressed by the
high-calcium diet, while paricalcitol reduced PTH without
influencing phosphate or calcium. The high-calcium diet
increased, while the high-phosphate diet reduced plasma
calcium. Plasma calcitriol was significantly reduced in other
remnant kidney groups, but further decreased after
paricalcitol. Cardiac perivascular fibrosis and connective
tissue growth factor were significantly increased in the
remnant kidney groups, and further increased in paricalcitol-
treated rats. Hence, regardless of the calcium, phosphate, or
PTH levels, cardiac perivascular fibrosis and connective tissue
growth factor increase in rats with renal insufficiency in
association with low calcitriol. Possible explanations are that
aggravated perivascular fibrosis after paricalcitol in renal
insufficiency may be due to further suppression of calcitriol,
or to a direct effect of the vitamin D analog.
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Cardiovascular complications are a major clinical problem in
chronic renal insufficiency (CRI).1 Secondary hypertension
due to excess volume load and left ventricular hypertrophy
are characteristic findings of uremia.2 Left ventricular
hypertrophy results in capillary–myocyte mismatch,3 which
impairs oxygen delivery to the cells, since cardiomyocytes
outgrow their capillary supply. Other morphological altera-
tions of the heart in CRI include increased interstitial fibrosis
and intramyocardial arteriolar wall thickness.3
The structural changes of the heart in CRI could result
from hypertension, volume overload, anemia, activation of
the local renin–angiotensin and endothelin systems, and
increased activity of the sympathetic nervous system.1,4
Disturbed calcium–phosphorus balance, reduced synthesis
of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and secondary
hyperparathyroidism also contribute to cardiac pathology in
CRI.1,4 Hyperphosphatemia may play an independent role in
the development of cardiac fibrosis and arterial wall
thickening,5 while parathyroid hormone (PTH) may be a
permissive factor for the development of cardiac hyper-
trophy, interstitial fibrosis, and arteriolar alterations.1
The synthesis of 1,25(OH)2D3 is catalyzed by 25-hydroxy-
vitamin D3-1a-hydroxylase, the expression of which has
been found in vascular smooth muscle cells, in addition to
epithelial cells of the nephrons.6 In vascular smooth muscle
cells, 1,25(OH)2D3 has an antiproliferative effect,
7 while in
the kidney 1,25(OH)2D3 is also a negative regulator of renin
expression.8 The cardiac hypertrophy seen in vitamin D
receptor (VDR) knockout mice appears to be a consequence
of activated systemic and local renin–angiotensin systems.9 In
cultured neonatal ventricular myocytes, 1,25(OH)2D3 also
inhibits proliferation, but increases cellular protein levels and
size, whereby it may induce cardiomyocyte hypertrophy.10
This study tested the hypothesis whether alterations in
calcium–phosphorus balance and calcium-regulating hormo-
nes could influence the structure of the heart in experi-
mental CRI. Treatment with the non-calcemic analog of
active vitamin D, paricalcitol (19-Nor), was used to reduce
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plasma PTH, increased calcium intake (Ca) was used to
suppress plasma phosphate and PTH, while increased
phosphate intake (Pi) was used to elevate these variables in
5/6 nephrectomized (NX) rats.
RESULTS
Animal data
The flow chart of the study is shown in Figure 1. Before the
diets at week 15, systolic blood pressure (BP) was higher in
NX than Sham rats (Table 1). At the end of the diets at week
27, the NX, NXþ Pi, and NXþ 19-Nor groups exhibited
further elevation of BP, whereas increased calcium intake
lowered BP in NX rats (NXþCa group). At the end of the
study, rats in the NXþCa and NXþ Pi groups weighed less
than Sham rats, while no significant differences in body
weights were observed between the NX groups. Heart weight-
to-body weight ratios were similarly increased in all NX
groups when compared with Sham rats (Table 1).
Laboratory findings
At study week 15, creatinine was equally elevated in all NX
groups. At study week 27, creatinine clearance was decreased
and plasma creatinine increased in all NX groups, while no
significant differences were detected between the NX groups
(Table 2). Plasma phosphate was increased in the NX and
NXþ 19-Nor groups, further elevated in the NXþ Pi group,
and reduced in the NXþCa group. Plasma PTH was
increased to 13-fold in the NX group, 41-fold in the NXþ Pi
group, 5-fold in the NXþ 19-Nor group, and suppressed to
about 5% of the level of Sham rats in the NXþCa group.
Plasma ionized calcium was increased in the NXþCa group,
and decreased in the NXþ Pi group. Blood pH was not
significantly different between the groups, while hemoglobin
was decreased in all NX rats when compared with Sham rats.
The hemoglobin values were also lower in the NXþ Pi and
NXþ 19-Nor groups than in the other groups (Table 2).
Plasma 1,25(OH)2D3 and 25-OH D3 were decreased in all
NX groups when compared with Sham rats, while
1,25(OH)2D3 was lowest in the NXþ 19-Nor group (Figure
2a and b). When compared with the Sham group, plasma
fibroblast growth factor 23 (FGF-23) concentrations were
markedly elevated in the NX, NX-Pi, and NXþ 19-Nor
groups, while lowest level was detected in the NXþCa group.
It is of note that plasma FGF-23 level was above the highest
detection limit in several rats of the NX, NX-Pi, and
NXþ 19-Nor groups (Table 2).
Plasma renin activity, ventricular angiotensin converting
enzyme, and atrial natriuretic peptide
Plasma renin activity was clearly reduced in all NX groups
irrespective of the diet and treatment (Figure 2c). The
angiotensin converting enzyme (ACE) content in cardiac
ventricles was higher in the NXþ Pi group than in the Sham
and NXþCa groups, while the NX, NXþCa, and NXþ
19-Nor groups did not significantly differ from the Sham group
(Figure 2d). The gene expression of atrial natriuretic peptide
(ANP) in cardiac ventricles was 8- to 10-fold increased in the
NX, NXþ Pi, and NXþ 19-Nor groups, while ventricular ANP
mRNA did not differ from Sham in the NXþCa group (Figure
2e). Ventricular ANP peptide content was also higher in the
NXþ Pi and NXþ 19-Nor groups when compared with Sham
and NXþCa rats, while the difference between the NX and
Sham groups was not significant (Figure 2f).
Histopathological evaluation and ventricular VDR mRNA
Perivascular fibrosis around small cardiac arteries was
increased in all NX groups, while highest fibrosis was
detected in the NXþ 19-Nor group (Figures 3a, 4a, and b).
In addition, the area of perivascular fibrosis was slightly
but significantly higher in the NXþ Pi than NXþCa rats.
In parallel, the number of cardiac connective tissue growth
factor (CTGF) positive cells was increased in all NX
groups, but highest CTGF expression was observed in the
NXþ 19-Nor group (Figures 3b, 4c, and d). No significant
differences in interstitial fibrosis and cardiomyocyte diameter
were detected between the groups (Figure 3c and d).
However, myocardial capillary density was reduced in all
NX groups, while capillary density was slightly higher in the
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Figure 1 | The study plan. The 5/6 nephrectomy (NX) or Sham
operation (Sham) was followed by a 15-week disease progression
period. Then the NX animals were divided into groups receiving
control diet (0.3% calcium, 0.5% phosphate), high-calcium diet
(Ca, 3%), high-phosphate diet (Pi, 1.5%), or paricalcitol treatment
(19-Nor, 200 ng/kg intraperitoneally, 3 days a week) for 12 weeks.
The n values denote to the number of animals/group at each phase
of the experiment.
Table 1 | Experimental group data
Sham NX NX+Ca NX+Pi
NX+19
-Nor
Body weight (g)
Week 15 50779 479710 483710 486713 48579
Week 27 56578 507741 481715* 431738* 503732
Systolic blood pressure (mm Hg)
Week 15 13572 15275* 15374* 15274* 15573*
Week 27 13072 17174* 14274*w 16174*z 16775*z
Heart/body
weight, g/kg
3.270.1 4.270.5* 4.070.2* 4.570.4* 4.570.3*
Ca, calcium intake; NX, nephrectomized; Pi, phosphate intake.
*Po0.05 versus Sham.
wPo0.05 versus NX.
zPo0.05 versus NX-Ca.
n=7–13.
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Table 2 | Laboratory findings
Sham NX NX+Ca NX+Pi NX+19-Nor
Creatinine clearance, ml/min/kg body weight 3.2770.19 1.4470.29* 1.7770.16* 1.4570.29* 1.3370.24*
Plasma
Creatinine (mmol/l)
Week 13 63.171.4 88.574.3* 91.673.9* 90.373.9* 88.773.6*
Week 27 66.672.2 170.0737.7* 116.577.3* 178.0730.9* 209.0741.7*
Phosphate (mmol/l) 1.2170.06 2.5370.54* 0.7270.06*w 5.4771.21*wz 3.0370.43*zy
PTH (pg/ml) 88712 11737370* 4.070.5*w 36207255*wz 4557220*wzy
Ionized calcium (mmol/l) 1.3570.01 1.3470.03 1.5770.03*w 0.9370.09*wz 1.3170.05zy
FGF-23 (pg/ml) 225729 41000* 86713*w 41600* 41600*
Blood pH 7.4170.02 7.3670.02 7.4070.02 7.3870.02 7.3870.02
Hemoglobin (g/l) 17571.9 148712.7* 15572.0* 110712.3*wz 119713.7*wz
Ca, calcium intake; FGF-23, fibroblast growth factor 23; NX, nephrectomized; Pi, phosphate intake; PTH, parathyroid hormone.
*Po0.05 versus Sham.
wPo0.05 versus NX.
zPo0.05 versus NX-Ca.
yPo0.05 versus NX-Pi.
n=7–11.
Notion concerning FGF-23 determinations: in the NX group three values were above the highest detection limit (1600 pg/ml), while in the NX+Pi and NX+19-Nor groups all
but one and all values, respectively, were above the highest detection limit.
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Figure 2 | Vitamin D status, indices of volume control and cardiac load. Plasma 1,25(OH)2D3 (a) and 25-OH D3 concentration (b),
plasma renin activity (c), ventricular angiotensin-converting enzyme (ACE) content (d), ventricular atrial natriuretic peptide (ANP) mRNA (e),
and ventricular ANP peptide content (f). Mean7s.e.m.; groups as in Figure 1, n¼ 7–11; *Po0.05 versus Sham, zPo0.05 NXþ 19-Nor versus
all other groups, and wPo0.05 versus NXþCa.
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NXþ 19-Nor group than in the NXþCa and NXþ Pi
groups (Figures 3e, 4e, and f). Ventricular VDR mRNA
content was similar in all groups (Figure 3e).
DISCUSSION
In the present study we examined whether alterations in
calcium–phosphorus–PTH–1,25(OH)2D3 balance could influ-
ence cardiac structure in experimental CRI. In order to
mimic clinical CRI, the rats were initially followed for 15
weeks after 5/6 nephrectomy, and thereafter the diets or
paricalcitol were given for 12 weeks. The study protocol was
successful in inducing clear changes in plasma concentrations
of calcium, phosphate, PTH, and 1,25(OH)2D3 in the
absence of significant differences in creatinine clearance in
the NX groups. The results for the first time demonstrated an
inverse relationship between the plasma 1,25(OH)2D3 and
the quantity of fibrosis around small cardiac arteries in CRI,
independent of the plasma levels of calcium, phosphate, and
PTH.
Plasma 1,25(OH)2D3 and 25-OH D3 levels were reduced
after NX, but were not affected by calcium or phosphate
diets. In contrast, paricalcitol treatment further suppressed
1,25(OH)2D3. The main regulators of 1,25(OH)2D3 synthesis
are phosphate, PTH, calcium, 1,25(OH)2D3, and FGF-
23.11–13 It is known that high normal plasma concentration
of phosphate inhibits and low normal stimulates
1,25(OH)2D3 synthesis. In addition, high PTH increases,
while hypercalcemia decreases the production. 1,25(OH)2D3
also regulates its own synthesis by a negative feedback
mechanism.11,12 FGF-23 suppresses 1,25(OH)2D3 levels via
reduction of 25-OH-D3-1a-hydroxylase and increase of
25-OH-D3-24-hydroxylase synthesis.
13 In the present study,
the suppression of 1,25(OH)2D3 following paricalcitol treat-
ment can be attributed to the direct reduction of active
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Figure 3 | Cardiac histomorphometry and vitamin D receptor (VDR). Effects of NX, high-calcium diet, high-phosphate diet, and paricalcitol
treatment in the heart: perivascular fibrosis (fibrosis area related to total wall area) (a), connective tissue growth factor (CTGF) expression
(number of positive cells per mm2 fibrosis area) (b), interstitial fibrosis (cumulative area mm2) (c), cardiomyocyte diameter (mm) (d), capillary
density (number per mm2 left ventricular area) (e), and vitamin D receptor (VDR) mRNA content (f). Mean7s.e.m.; groups as in Figure 1,
n¼ 7–11; *Po0.05 NX versus Sham, wPo0.05 versus NXþCa, yPo0.05 versus NXþ Pi, and zPo0.05 NXþ 19-Nor versus all groups.
980 Kidney International (2007) 72, 977–984
o r i g i n a l a r t i c l e JM Repo et al.: Low calcitriol and perivascular fibrosis
vitamin D metabolite synthesis by this agonist,14 whereas
suppression of plasma phosphate and the subsequent
reduction of FGF-23 level can explain why high calcium
intake did not reduce 1,25(OH)2D3 concentrations.
Alterations in calcium–phosphorus balance and calcium-
regulating hormones are known causes for cardiovascular
complications in CRI.15,16 In particular, elevated calcium–
phosphate product and hyperphosphatemia have been
implicated in cardiovascular calcification and poor outcome
in the dialysis population.16,17 However, altered vitamin D
status may also contribute to the cardiovascular pathology in
CRI.4 Changes in vitamin D metabolism can influence the
function of various tissues, including vascular smooth muscle
and the heart.12,18 Treatment of secondary hyperparathyroid-
ism by the use of intravenous 1,25(OH)2D3 has been found
to induce regression of myocardial hypertrophy in hemodia-
lysis patients.19,20 In rats, depletion of vitamin D3 has been
found to increase heart weight due to increased myocardial
collagen accumulation.21 In the kidney, 1,25(OH)2D3 inhibits
interstitial myofibroblast activation,22 while in human
fibroblast cell lines 1,25(OH)2D3 inhibits the production of
interleukins 6 and 8.23 In mouse fibroblasts, VDR plays an
inhibitory role in the regulation of nuclear factor-kappa B
activation, while cells lacking VDR were found to be more
susceptible to inflammatory stimulation.24 Taken together,
reduced 1,25(OH)2D3 level may play a significant role in the
enhanced fibrogenesis in CRI.18
The VDR is found ubiquitously throughout the body, and
in the parathyroid cells, osteoblasts, and intestinal enter-
ocytes, its action has been well characterized. However, the
function of VDR in many other tissues has not been
established.25 The heart as a whole shows low level of VDR
expression, while in tissues containing higher proportion of
fibrous elements, like the aorta and pericardium, the
expression is higher.14 In the present study, plasma
1,25(OH)2D3 concentration was similarly reduced in the
NX, NXþCa, and NXþ Pi groups, which showed 15–25%
increases in cardiac perivascular fibrosis, at different levels of
plasma phosphate, calcium, and PTH. In the NXþ 19-Nor
group, plasma 1,25(OH)2D3 was reduced by 98% and
perivascular fibrosis was increased by 45%, in the absence
of changes in plasma phosphate and calcium levels, while
PTH was reduced by 60% when compared with the untreated
NX group. Several factors, including transforming growth
factor-b1, angiotensin II, and basic FGF are known to play a
role in the initiation of fibrogenesis,26,27 while CTGF has been
implicated as the major long-term mediator in this process.26
We found that the amount of CTGF-positive cells in the
perivascular area was increased in all NX groups, but was
highest in the NXþ 19-Nor group. High CTGF labeling
indicates that fibrogenesis was an active growth factor-
mediated process. Collectively these results suggest that
reduced 1,25(OH)2D3 played a significant role in the
enhanced cardiac perivascular fibrosis in NX rats, probably
via enhanced growth factor expression, and raise the
possibility that paricalcitol indirectly increased fibrosis by
suppressing 1,25(OH)2D3. Changes in VDR expression did
not explain the results, since cardiac VDR expression was
similar in all study groups.
Despite almost similar affinity for the VDR, paricalcitol is
about 10 times less calcemic than 1,25(OH)2D3.
14,28 Par-
icalcitol is less potent in mobilizing calcium and phosphorus
from bone, and induces lower stimulation of intestinal
calcium transport proteins than 1,25(OH)2D3.
28,29 VDR is a
cellular receptor that acts as a ligand-activated transcription
factor. Upon binding to the VDR, 1,25(OH)2D3 produces a
conformational change in the receptor that allows it to bind
with the retinoid X receptor. The VDR/retinoid X receptor
complex binds to the target gene promoter, which recruits
other components of the transcriptional initiation complex,
and subsequently influences gene transcription.25,28 In the
kidney, VDR expression is responsible for upregulating at
least 50 genes and downregulating 40 genes.30 Vitamin D
a
c
b
d
e f
Figure 4 | Cardiac histology. Representative original
photomicrographs showing cardiac perivascular fibrosis
(marked with an asterisk) in the Sham (a) and NXþ 19-Nor groups (b),
CTGF-positive cells (marked with an arrow; nuclei and cytoplasm
of positive cells are stained brown) in the wall of a myocardial
artery in the Sham (c) and NXþ 19-Nor groups (d), and myocardial
capillary density (arrow; the specific endothelial marker factor VIII
is stained brown) in the Sham (e) and NX groups (f).
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analogs may produce distinct conformational changes in the
VDR, which could alter binding with the retinoid X receptor,
resulting in altered interaction with the vitamin D responsive
element.28 Differential recruitment of co-activators or co-
repressors to the transcriptional initiation complex may play
a role in the biological actions of vitamin D analogs.28 On the
basis of the present results, the possibility remains that
1,25(OH)2D3 and paricalcitol could exert different influences
on the growth of perivascular connective tissue, and
increased fibrosis after paricalcitol treatment could have
resulted from a direct effect of the compound on the growth
of fibrous tissue.
In concert with several previous reports,3,31 we found that
myocardial capillary density was reduced in all NX groups,
while no differences in interstitial fibrosis and cardiomyocyte
diameter were detected between the groups. Previously, in an
8-week study using perfusion fixation techniques for tissue
sampling, intramyocardial arteriolar wall thickening, reduced
intramyocardial capillary length density, and increased
interstitial volume density were reported in NX rats.31 In
another 8-week experiment using perfusion fixation, the
index of interstitial cardiac fibrosis and myocardial arterial
wall thickness were increased following high phosphorus
intake in NX rats.5 The discrepancies between the present and
the above reports may be related to tissue sample harvesting
techniques. We applied immersion fixation to retain the
possibilities for mRNA measurements and autoradiography
from the cardiac samples in this 27-week study.
Although 1,25(OH)2D3 has been linked to the formation
of arterial calcifications in poorly understood manner, and in
vitro studies suggest that 1,25(OH)2D3 may have a stimula-
tory effect on vascular calcification,32,33 treatment with
vitamin D has shown mortality benefit in dialysis patients.34
An observational finding suggests that patients who receive
paricalcitol while undergoing long-term hemodialysis may
even have a survival advantage over those who receive
1,25(OH)2D3.
35 While the present results seem to contradict
the above findings concerning the benefits of paricalcitol
therapy, we found a small increase in myocardial capillary
density in the NXþ 19-Nor group, when compared with in
the NXþCa and NXþ Pi groups. Our findings implicate
that the long-term effect of vitamin D status and paricalcitol
treatment on myocardial perfusion should be addressed in
the future. The present results raise the question whether
dialysis patients, who are treated with high doses of
paricalcitol for secondary hyperparathyroidism, should also
be supplemented with 1,25(OH)2D3 to normalize their
vitamin D status.
The 5/6 nephrectomy is a model of CRI with volume
overload,36 and we found that plasma renin activity was
decreased, and cardiac weight and ventricular ANP mRNA
increased in the NX group when compared with the Sham
group. Calcium diet reduced BP and ventricular ANP mRNA,
probably because it has a natriuretic effect and reduces
kidney ACE expression.36,37 The above structural changes of
the heart in CRI could also have resulted from elevated BP,
volume overload, and activation of the local renin–angio-
tensin system. However, in this study the amount of
perivascular fibrosis was not strongly related to these factors,
since high calcium intake did not decrease cardiac CTGF or
perivascular fibrosis in NX rats. Furthermore, the differences
in fibrosis between the NX groups could not be attributed to
anemia either, since the NXþ Pi and NXþ 19-Nor groups
showed corresponding reductions in hemoglobin but clear
differences in the quantity of perivascular fibrous tissue.
In summary, our results in this low-renin model of CRI
showed an inverse relationship between active vitamin D
levels and perivascular fibrosis in the heart, while paricalcitol
treatment that further suppressed 1,25(OH)2D3 also aggra-
vated the fibrosis. These findings suggest that low circulating
levels of 1,25(OH)2D3, or paricalcitol treatment directly, may
predispose to increased perivascular fibrosis in renal
insufficiency.
MATERIALS AND METHODS
Animals and experimental design
Systolic BPs of male Sprague–Dawley rats, obtained from the colony
of Tampere University, were measured using tail-cuff (Model 129 BP
Meter; IITC Inc., Woodland Hills, CA, USA). Standard rat chow
contained 0.9% calcium, 0.8% phosphate, 0.27% sodium, 1500 IU/
kg vitamin D, and 12550 kJ/kg energy (Lactamin R34, AnalyCen,
Lindko¨ping, Sweden). The 5/6 nephrectomy or Sham operation was
carried out at the age of 8 weeks, as described previously.38,39 After a
15-week-long disease progression period, the NX rats were divided
into four groups with equal systolic BPs, body weights, urine
outputs, and plasma creatinines. Then for 12 weeks, the Sham, NX,
and NXþ 19-Nor groups continued on 0.3% calcium and 0.5%
phosphate, NXþCa group on 3.0% calcium and 0.5% phosphate,
NXþ Pi group on 0.3% calcium and 1.5% phosphate, and the
NXþ 19-Nor group received 200 ng/kg of 19-Nor-1,25(OH)2D2
(intravenous injection solution of paricalcitol, 5 mg/ml, vehicle
containing 30% propylene glycol and 20% ethanol) intraperitoneally
3 days a week (Figure 1). Since the vehicle volume in each
paricalcitol injection was only about 10 ml, no vehicle-treated group
was included in the study.
The final animal numbers in the Sham, NX, NXþCa, NXþ Pi,
and NXþ 19-Nor groups were 10, 7, 11, 7, and 8, respectively.
During the final study week, 24-h urine was collected using
metabolic cages. Then the rats were weighed and anesthetized
(intraperitoneal urethane 1.3 g/kg), and blood samples from
cannulated carotid artery were drawn into chilled tubes with
heparin or ethylenediaminetetraacetic acid as anticoagulant. The
hearts and kidneys were rapidly removed and weighed. After rinsing
the heart with physiological salt solution, the right and left auricles
were removed, and the remaining atrial tissue, aorta, and pulmonary
artery were carefully cut close to the ventricular surface. The
ventricles were cut into superior (about 20% of total weight) and
inferior parts, the former for histological analyses and the latter for
ANP, VDR, and ACE determinations. The inferior part samples were
blotted dry, weighed, snap-frozen with isopentane at 401C, and
stored at 701C.38,39
All rats were housed 3–4 per cage in an animal laboratory
(illuminated 0600–1800 h, temperature þ 221C) with free access to
water and food. The study design was approved by Tampere
University Animal Experimentation Committee, and Provincial
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Government of Western Finland, Department of Social Affairs and
Health, Finland. The investigation conforms to the Guiding
Principles for Research Involving Animals. The investigation con-
forms to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publication
No. 85–23, revised 1996).
Immunohistochemistry, and histopathological analysis of
hearts
After fixation in 4% formaldehyde for 24 h, the cardiac specimens
were processed into paraffin. For histological examination, Herovici
and periodic acid-Schiff stainings were used. For immunohisto-
chemistry, CTGF antibody (1:800; Abcam Ltd, Cambridge, UK) and
factor VIII antibody (1:1000; Dako Cytomation A/S, Glostrup,
Denmark) were used to assess CTGF labeling and capillary density
in the cardiac samples. For immunohistochemical stainings, 3 mm
paraffin sections were cut onto ChemMateTM capillary gap micro-
scopic slides (Dako Cytomation A/S). Antigen retrieval for CTGF
antibody and factor VIII antibody was performed on rehydrated
sections in a microwave oven at 850 W for two 7-min cycles using
Tris-ethylenediaminetetraacetic acid buffer (pH 9.0) as retrieval
solution. Immunoperoxidase staining was then carried out in a
TechMateTM 500 Immunostainer (Dako Cytomation A/S) using the
EnVisionTM polymer technique (Dako Cytomation A/S). Diamino-
benzidine was used as a chromogen, and hematoxylin as a nuclear
stain. For negative controls, the primary antibodies were omitted. To
confirm the staining reliability of separate staining batches, known
positive tissue samples were used.
All histomorphometrical investigations were performed in a
blinded manner, so that the observer was unaware of the study
group. Stereological analysis was performed on 10 random
intramyocardial arteries, or on 15 random samples of differently
orientated sections of left ventricular myocardium per animal.
Arteries were included if they had a clear lumen visible. Perivascular
fibrosis, interstitial tissue, CTGF expression, and capillary density
were obtained using the point-counting method, according to the
equation Pp¼Vv (Pp is point density), using a 100-point square
lattice in the eyepiece, in 12 fields of the selected area.
Immunoperoxidase staining results were investigated at original
magnification  400 with an ocular grid (0.0625 mm2).40 CTGF-
positive cells were counted as the number of cells per mm2 of
fibrosis area. Perivascular fibrosis was obtained as fibrosis area
related to total wall area, and interstial fibrosis as cumulative area
(mm2) related to myocardium. Capillary density was counted as the
number of capillaries per mm2 left ventricular area. Cardiomyocyte
diameter was measured as lesser fiber diameter (mm) on 100 fibers
per animal using an interactive image analysis program (AnalySIS
Soft Imaging System GmbH, Mu¨nster, Germany).
Cardiac ANP, ACE and VDR, plasma renin activity, vitamin D,
FGF-23, electrolytes, phosphate, PTH, creatinine clearance,
and hemoglobin determinations
Total RNA was isolated from cardiac tissue samples, and 20 mg of
ventricular RNA was transferred to MAGNA nylon membrane
(Osmonics Inc., Minnetonka, MN, USA). Polymerase chain
reaction-amplified probes to 922–1403 of rat ribosomal 18S RNA
(M11188) and full-length rat ANP cDNA probe Car-55 (provided by
Dr PL Davies, Queen’s University, Kingston, Canada) were labeled
and handled as previously,41 with the modification that after
hybridization the membranes were washed at þ 601C and exposed
to Phosphor screens (Eastman Kodak, Rochester, NY, USA).
Radioactivity was measured by PhosphorImager SI and ImageQuant
software (Molecular Dynamics, Sunnyvale, CA, USA). VDR mRNA
levels were measured by reverse transcriptase-polymerase chain
reaction using TaqMan chemistry on ABI 7700 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) as described
previously.42 The sequences of the forward (F) and reverse (R)
primers and for fluorogenic probes (P) for RNA detection were:
VDR (F) 50-TGTGAAGGCTGCAAAGGTTTC-30, (R) 50-AGGGACA
GGTGAACAGGGC-30, (P) 50-Fam-TCAGGCGGAGCATGAAGCG
GA-Tamra-30 and 18S (F) 50-TGGTTGCAAAGCTGAAACTTAAA
G-30, (R) 50-AGTCAAATTAAGCCGCAGGC-30, (P) 50-Vic-CCTGG
TGGTGCCCTTCCGTCA-Tamra-30. ANP and VDR mRNA was
normalized to 18S in each sample.
Radioimmunoassay for ANP was carried out as described
previously.41,43 The autoradiography of cardiac ACE was performed
on 20-mm thick tissue sections with the radioligand [125I]-MK351A
as described earlier.36,44 Plasma renin activity (Ang I RIA kit;
Diasorin S.p.a., Saluggia, Italy), 1,25(OH)2D3, and 25-OH D3 (IDS
Ltd, Boldon, UK) were determined using commercial kits. Plasma
FGF-23 was determined by Human FGF-23 ELISA kit (Kinos Inc.,
Tokyo, Japan), which has previously been applied for analyses in
rats.45 Plasma phosphate was measured by colorimetric dry
chemistry (Vitros 950 analyzer, Johnson & Johnson Clinical
Diagnostics, Rochester, NY, USA). Plasma calcium was measured
by ion selective electrode (634 Ca2þ /pH Analyzer, Ciba Corning
Diagnostics, Sudbury, UK), and PTH was quantified by immunor-
adiometric assay specific for intact rat PTH (Immutopics, San
Clemente, CA, USA). Creatinine was determined by colorimetric
assay according to Jaffe, and creatinine clearance as¼ (urine
creatinine urine volume)/plasma creatinine. Hemoglobin was
measured photometrically (Technicon H*2TM, Technicon Instru-
ments Corporation, Tarrytown, NY, USA).
Data presentation and analysis of results
Statistical analysis was by one-way analysis of variance and the least-
significant difference test. If variable distribution was skewed, the
Kruskal–Wallis and Mann–Whitney U-tests were applied, and
P-values were corrected with the Bonferroni equation. Spearman’s
two-tailed correlation coefficient (r) was used in the correlation
analyses. Results were expressed as mean7s.e.m., and Po0.05
denoted significance.
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